NeoGenomics (NEO) Tops Q4 EPS by 1c, Revenues Beat; Offers FY19 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
NeoGenomics Reports Record Revenue of $76 Million with 17% Organic Revenue Growth in the Fourth Quarter
February 19, 2019 7:01 AM ESTFT. MYERS, Fla., Feb. 19, 2019 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2018.
Fourth Quarter 2018 Highlights:
Consolidated revenue increased 24.5% to $76.5 million Consolidated revenue increased 17.0% to $71.8 million, excluding GenoptixClinical Services revenue increased 23.3% to $65.9 million Pharma Services revenue increased 32.6% to $10.6 millionGross profit increased 38.7% to $37.1 millionGross margin increased... More